Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI

IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy

Granules India appoints Ramraj Rangarajulu as President and Head - Formulations Operations

He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024

Akums appoints Amrut Medhekar as CEO - CDMO Business

e brings over 27+ years of rich pharmaceutical experience

Sentynl Therapeutics receives marketing authorization for Nulibry from UK MHRA

NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A

Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India

Vericiguat works on a pathway not currently targeted by existing heart failure treatments

Ipca appoints Hitesh Kumar Maheshwari as President – R&D (Formulations)

He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company

India's Medical Value sector projected to reach $ 13 billion by 2026: Dr Mandaviya

Need to harmonize traditional and modern medicine to combat alarming health problems

Industry needs to establish a self-regulatory body to maintain the quality of the pharma products, says Dr Mandaviya

BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin

NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.

Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners

Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.